Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy

Détails

Ressource 1Télécharger: serval:BIB_330436096753.P001 (148.70 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_330436096753
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy
Périodique
Clinical Infectious Diseases
Auteur(s)
Cometta  A., Kern  W. V., De Bock  R., Paesmans  M., Vandenbergh  M., Crokaert  F., Engelhard  D., Marchetti  O., Akan  H., Skoutelis  A., Korten  V., Vandercam  M., Gaya  H., Padmos  A., Klastersky  J., Zinner  S., Glauser  M. P., Calandra  T., Viscoli  C.
ISSN
1537-6591 (Electronic)
Statut éditorial
Publié
Date de publication
08/2003
Volume
37
Numéro
3
Pages
382-9
Notes
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Aug 1
Résumé
This prospective, double-blind trial assessed whether the addition of a glycopeptide would be able to reduce the time to defervescence in neutropenic patients with cancer who had persistent fever 48-60 h after the initiation of empirical piperacillin-tazobactam monotherapy. Of 763 eligible patients, 165 with persistent fever were randomized to receive piperacillin-tazobactam therapy plus either vancomycin therapy or placebo. Defervescence was observed in 82 (95%) of 86 patients in the vancomycin group and in 73 (92%) of 79 patients in the placebo group (P=.52). The distributions of the time to defervescence were not statistically significant between the 2 groups (estimated hazard ratio, 1.03; 95% confidence interval, 0.75-1.43; P=.75). The number of additional episodes of gram-positive bacteremia and the percentage of patients for whom amphotericin B was empirically added to their therapy regimen were also similar in both groups. This study failed to demonstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently febrile neutropenic patients with cancer.
Mots-clé
Adolescent Adult Aged Child Child, Preschool Double-Blind Method Fever/chemically induced/*drug therapy Humans Middle Aged Neoplasms/complications/*drug therapy/physiopathology Neutropenia/etiology Penicillanic Acid/*adverse effects/analogs & derivatives/therapeutic use Piperacillin/*adverse effects/therapeutic use Treatment Outcome Vancomycin/*therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 14:31
Dernière modification de la notice
25/09/2019 7:08
Données d'usage